{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T21:05:43Z","timestamp":1786309543126,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,10]],"date-time":"2014-11-10T00:00:00Z","timestamp":1415577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.euroneuro.2014.09.014","type":"journal-article","created":{"date-parts":[[2014,10,23]],"date-time":"2014-10-23T02:00:50Z","timestamp":1414029650000},"page":"1861-1872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit\/hyperactivity disorder: A randomized, controlled, Phase III trial"],"prefix":"10.1016","volume":"24","author":[{"given":"Amaia","family":"Hervas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1113-8537","authenticated-orcid":false,"given":"Michael","family":"Huss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McNicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"van Stralen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Sreckovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Bloomfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Sikirica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2014.09.014_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40263-013-0095-5","article-title":"Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder","volume":"27","author":"Banaschewski","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/chi.0b013e31815d88b2","article-title":"Meta-analysis of suicide-related behavior events in patients treated with atomoxetine","volume":"47","author":"Bangs","year":"2008","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1542\/peds.86.2.184","article-title":"Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation","volume":"86","author":"Barkley","year":"1990","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0140-6736(05)66915-2","article-title":"Attention-deficit hyperactivity disorder","volume":"366","author":"Biederman","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1017\/S1092852900017107","article-title":"Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD","volume":"13","author":"Biederman","year":"2008","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib6","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1542\/peds.2006-3695","article-title":"A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"121","author":"Biederman","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1176\/ajp.94.3.577","article-title":"The behavior of children receiving Benzedrine","volume":"94","author":"Bradley","year":"1937","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/0269881113478475","article-title":"Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009\u20132011: focus on clinical efficacy and safety","volume":"28","author":"Bushe","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib9","unstructured":"CADDRA, 2011. CADDRA Canadian ADHD practice guidelines third edition: download. Available at: \u3008http:\/\/caddra.ca\/cms4\/index.php?option=com_content&view=article&id=14&Itemid=36&lang=en\u3009 (accessed 22.10.14.)."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib10","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/00004583-199509000-00010","article-title":"Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette\u05f3s syndrome: preliminary clinical experience","volume":"34","author":"Chappell","year":"1995","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40263-013-0130-6","article-title":"Attention-deficit\/hyperactivity disorder with inadequate response to stimulants: approaches to management","volume":"28","author":"Childress","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib12","first-page":"755","article-title":"Effects of guanfacine extended release on oppositional symptoms in children aged 6\u201312 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Connor","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/jcpp.12036","article-title":"Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents","volume":"54","author":"Cortese","year":"2013","journal-title":"J. Child Psychol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib14","unstructured":"DuPaul, G.J., Power, T.J., Anastopoulos, A.D., Reid, R., 1998. ADHD Rating Scale-IV (for Children and Adolescents): Checklists, Norms, and Clinical Interpretation. Guilford Publications Inc., NewYork, NY."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib15","unstructured":"Eli Lilly and Co, 2007. A 3-month, open-label study of atomoxetine in children with attention-deficit\/hyperactivity disorder; symptomatic and functional outcomes. Available at: \u3008http:\/\/www.clinicalstudyresults.org\u3009 (accessed 08.10.13.)."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib16","unstructured":"Eli Lilly and Co, 2008. A study comparing the effect of atomoxetine vs. other standard care therapy on the long term functioning in ADHD children and adolescents (ADHD LIFE). Available at: \u3008http:\/\/clinicaltrials.gov\/ct\/show\/NCT00447278\u3009 (accessed 08.10.13.)."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib17","unstructured":"EMC, 2013. Strattera Summary of Product Characteristics. Available at: \u3008http:\/\/www.medicines.org.uk\/emc\/medicine\/14482\u3009. (accessed 10.02.14.)."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00787-010-0140-6","article-title":"European guidelines on managing adverse effects of medication for ADHD","volume":"20","author":"Graham","year":"2011","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib19","series-title":"Clinical Global Impressions: Early Clinical Drug Evaluation Unit Assessment Manual for Psychopharmacology (Gov Pubs\/US: HE 20.8108:P 95\/2\/976)","author":"Guy","year":"1976"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib20","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3109\/10398562.2010.498049","article-title":"Review of attention-deficit\/hyperactivity disorder comorbid with oppositional defiant disorder","volume":"18","author":"Hazell","year":"2010","journal-title":"Australas. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib21","unstructured":"Health Canada, 2014. Canadian Intuniv license. Available at: \u3008http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/sbd-smd\/drug-med\/sbd_smd_2013_ituniv_xr_150741-eng.php\u3009 (accessed 20.08.14.)."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaac.2013.11.009","article-title":"Alpha-2 agonists for attention-deficit\/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy","volume":"53","author":"Hirota","year":"2014","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/104454601750143500","article-title":"A revised anchored version of the BPRS-C for childhood psychiatric disorders","volume":"11","author":"Hughes","year":"2001","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/cap.2010.0064","article-title":"Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit\/hyperactivity disorder","volume":"21","author":"Kollins","year":"2011","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/104454601750284072","article-title":"An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder","volume":"11","author":"Kratochvil","year":"2001","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00004583-200207000-00008","article-title":"Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial","volume":"41","author":"Kratochvil","year":"2002","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.20701","article-title":"Noradrenergic modulation of space exploration in visual neglect","volume":"59","author":"Malhotra","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/cap.2008.0166","article-title":"Atomoxetine and neuropsychological function in children with attention-deficit\/hyperactivity disorder: results of a pilot study","volume":"19","author":"Maziade","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib29","unstructured":"MedDRA, 2009. MedDRA version 12.1. Available at: \u3008http:\/\/www.meddra.org\/\u3009 (accessed 28.11.13.)"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib30","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1176\/appi.ajp.159.11.1896","article-title":"Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study","volume":"159","author":"Michelson","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib31","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaac.2013.06.006","article-title":"Randomized, double-blind trial of guanfacine extended release in children with attention-deficit\/hyperactivity disorder: morning or evening administration","volume":"52","author":"Newcorn","year":"2013","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib32","unstructured":"NIH, 2014. Intuniv Summary of Product Characteristics. Available at: \u3008http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=b972af81-3a37-40be-9fe1-3ddf59852528\u3009 (accessed 24.04.14.)."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib33","first-page":"S117","article-title":"New options in the pharmacological management of attention-deficit\/hyperactivity disorder","volume":"10","author":"Olfson","year":"2004","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib34","first-page":"10","article-title":"The Brief Psychiatric Rating Scale for children","volume":"18","author":"Overall","year":"1982","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib35","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1176\/ajp.2007.164.6.942","article-title":"The worldwide prevalence of ADHD: a systematic review and metaregression analysis","volume":"164","author":"Polanczyk","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib36","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","article-title":"Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA\u05f3s pediatric suicidal risk analysis of antidepressants","volume":"164","author":"Posner","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/cap.2008.0080","article-title":"Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"19","author":"Sallee","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CHI.0b013e318191769e","article-title":"Guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder: a placebo-controlled trial","volume":"48","author":"Sallee","year":"2009","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib39","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","article-title":"A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder","volume":"158","author":"Scahill","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00213-012-2893-8","article-title":"Guanfacine modulates the influence of emotional cues on prefrontal cortex activation for cognitive control","volume":"226","author":"Schulz","year":"2013","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib41","unstructured":"Shire, 2014. Intuniv US FDA label. Available at: \u3008http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022037s002lbl.pdf\u3009 (accessed 20.08.14.)."},{"issue":"Suppl. 2","key":"10.1016\/j.euroneuro.2014.09.014_bib42","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1002\/pds.3246","article-title":"Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder","volume":"21","author":"Signorovitch","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib43","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40263-013-0102-x","article-title":"Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit\/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology","volume":"27","author":"Sikirica","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib44","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0031-3955(05)70166-8","article-title":"Alternative (nonstimulant) medications in the treatment of attention-deficit\/hyperactivity disorder in children","volume":"46","author":"Silver","year":"1999","journal-title":"Pediatr. Clin. N. Am."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib45","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/jnnp.2009.195792","article-title":"Attention deficits following ADEM ameliorated by guanfacine","volume":"82","author":"Singh-Curry","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/10445460152595577","article-title":"An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder","volume":"11","author":"Spencer","year":"2001","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib47","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.4088\/JCP.v63n1209","article-title":"Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit\/hyperactivity disorder","volume":"63","author":"Spencer","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib48","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/cap.2008.0152","article-title":"Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"19","author":"Spencer","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib49","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1089\/cap.2011.0018","article-title":"Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts","volume":"21","author":"Stein","year":"2011","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib50","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-0773.1995.tb00161.x","article-title":"Comparison of the binding activities of some drugs on alpha 2A, alpha 2B and alpha 2C-adrenoceptors and non-adrenergic imidazoline sites in the guinea pig","volume":"76","author":"Uhlen","year":"1995","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-2999(91)90299-6","article-title":"Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound","volume":"202","author":"Uhlen","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2007.03.015","article-title":"Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex","volume":"129","author":"Wang","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.euroneuro.2014.09.014_bib53","unstructured":"Weiss, M.D., Brooks, B.L., Iverson, G.L., Lee, B., 2007. Reliability and validity of the Weiss functional impairment rating scale [abstract]. In: proceedings of the AACAP 54th Annual Meeting Program, Boston, MA, 23\u201328 October."},{"key":"10.1016\/j.euroneuro.2014.09.014_bib54","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1542\/peds.2011-2654","article-title":"ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents","volume":"128","author":"Wolraich","year":"2011","journal-title":"Pediatrics"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14002788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14002788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:50:48Z","timestamp":1760377848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X14002788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0924977X14002788"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.09.014","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit\/hyperactivity disorder: A randomized, controlled, Phase III trial","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and ECNP.","name":"copyright","label":"Copyright"}]}}